4 results
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
Primary- To determine the validity of home-based self-monitoring of VC in patients with MND.Secondary- To determine the reliability of home-based self-monitoring of VC in patients with MND.- To evaluate the feasibility of 4-weekly home-based self-…
Primary Safety Objective: To describe the safety profile of 20vPnC
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…